Sales and earnings rose sharply, led by Specialty Chemicals, with EBITDA up 36% and net income up 66% year-over-year. Major investments in nitroguanidine capacity and sustainability initiatives were announced, and guidance points to higher margins despite sales at the lower end of the range.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.